Last updated: 3 months ago
Portage Biotech Inc. 6-K Report: Nasdaq Compliance Plan Accepted
Portage Biotech Inc. files Form 6-K detailing Nasdaq's acceptance of its compliance plan. Key insights on financial health and operational status included.
Posts With Tag Portage Biotech Inc.
Showing 1 - 2 of 2 Posts
Last updated: 4 months ago
Portage Biotech Inc. Unveils Cyncado Therapeutics™: A Bold New Chapter
On January 6, 2025, Portage Biotech Inc. re-launches Cyncado Therapeutics™ with CEO Peter Molloy, focusing on adenosine receptor antagonists. Key insights from the Form 6-K.